JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Opdivo gained rapid approval in the US after having gained 'Breakthrough Therapy Designation', and was also identified as a promising innovative medicine (PIM) for lung cancer by the UK's drug ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...

J&J has already benefitted from Halozyme’s ENHANZE tech with DARZALEX, and it looks as if OPDIVO might be another blockbuster drug that could benefit from ENHANZE tech. Essentially, Halozyme offers ...

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...